HPLC

:   high‐performance liquid chromatography

UV

:   ultraviolet

LOQ

:   limit of quantification

*D*

:   priming dosepriming/loading‐ a relatively large dose given at the beginning of therapy to get desired pharmacological/ antimicrobial effect at the earliest

*D*\'

:   maintenance dose -- a dose given during course of therapy to maintain desired pharmacological effect produced by the priming/loading dose

*F*

:   bioavailability defined as percent of drug available in the central compartment after drug administration

Introduction {#vms310-sec-0001}
============

Enrofloxacin \[(1‐cyclopropyl)‐7‐(ethyl‐1‐piperazinyl)‐ 6‐fluoro‐1,4‐dihydro‐4‐oxo‐3‐quinoline carboxylic acid\] is a fluoroquinolone antibacterial developed exclusively for veterinary use (Altreuther [1987](#vms310-bib-0003){ref-type="ref"}). It is characterized by the presence of a fluorine atom at position 6 and the presence of a piperazinyl or pyrrolidinyl substituent in position 7 of the quinoline nucleus (Gips & Soback [1996](#vms310-bib-0014){ref-type="ref"}). The mode of action of fluoroquinolones involves interactions with DNA gyrase, the originally recognized drug target and also topoisomerase IV, a related type II topoisomerase (Hooper [1999](#vms310-bib-0015){ref-type="ref"}). It also possesses post‐antibiotic effect (McKellar [1996](#vms310-bib-0022){ref-type="ref"}). It is metabolized by de‐ethylation to another fluoroquinolone ciprofloxacin (Kung *et al*. [1993](#vms310-bib-0020){ref-type="ref"}), giving sustained activity at the same dose rate compared to other fluoroquinolones. It is indicated against various bacterial infections such as *Escherichia coli, Staphylococcus aureus, Streptococcus pneumonia, Legionella pneumophila, Moraxella catarrhalis, Pseudomonas aeruginosa, Haemophilus influenza* and *Haemophilus ducreyi*. Sanders ([1988](#vms310-bib-0031){ref-type="ref"}) resulting in septicaemia, respiratory tract, urinary tract, skin, soft tissue, bone and joint infections (McKellar *et al*. [1999](#vms310-bib-0023){ref-type="ref"}; Sanjib *et al*. [2005](#vms310-bib-0032){ref-type="ref"}). Recent reports indicate the use of enrofloxacin in bovine respiratory disease associated with *Pasteurella multocida* and *Mannheimia (M.) haemolytica* (Balaje *et al*. [2013](#vms310-bib-0004){ref-type="ref"}).

The pharmacokinetic behaviour of enrofloxacin after intravascular administration has been determined in cattle (Kaartinen *et al*. [1995](#vms310-bib-0017){ref-type="ref"}, [1997](#vms310-bib-0018){ref-type="ref"}; Malbe *et al*. [1996](#vms310-bib-0021){ref-type="ref"}), goats (Elmas *et al*. [2001](#vms310-bib-0008){ref-type="ref"}; Elsheikh *et al*. [2002](#vms310-bib-0009){ref-type="ref"}; Rao *et al*. [2002](#vms310-bib-0029){ref-type="ref"}) and other ruminants (Gavrielli *et al*. [1995](#vms310-bib-0012){ref-type="ref"}; Christensen *et al*. [1996](#vms310-bib-0006){ref-type="ref"}) at the dose rate of 2.5--5 mg kg^−1^ body weight. Some studies on pharmacokinetics of enrofloxacin and ciprofloxacin have been performed in buffalo calves through intravenous (i.v.) and intramuscular (i.m.) routes (Saini & Srivastava [2001](#vms310-bib-0030){ref-type="ref"}; Sharma *et al*. [2003](#vms310-bib-0033){ref-type="ref"}; Balaje *et al*. [2013](#vms310-bib-0004){ref-type="ref"}; Kumar & Jayachandran [2013](#vms310-bib-0019){ref-type="ref"}). Enrofloxacin exhibited good absorption, large volume of distribution and half‐life in the range of 2--6 h (Otero *et al*. [2009](#vms310-bib-0027){ref-type="ref"}). Once kinetics of a drug is performed, it\'s pharmacokinetic--pharmacodynamic (PK‐PD) relationship has to be determined, which is the most significant predictor of the efficacy of fluoroquinolones (Balaje *et al*. [2013](#vms310-bib-0004){ref-type="ref"}).

The present study aims at exploring the pharmacokinetics of a new preparation of enrofloxacin, thereby arriving at PK‐PD integration as well as calculation of dosage regimen, using pharmacodynamic data previously established in the laboratory.

Materials and methods {#vms310-sec-0002}
=====================

The experiment was conducted on six male buffalo calves of 6--12 months age (weight 90--120 kg). The experiment protocol followed the guideline on proper care and handling of animals and was approved by the Institutional Animal Ethics Committee. Calves were given both i.v. and i.m. administrations in a complete crossover design with a washout period of 3 weeks minimum between two treatments. Enrofloxacin 10% (Flobac SA^®^; Intas Pharmaceuticals Pvt. Ltd., Ahmedabad, India) was administered through jugular vein and deep gluteal muscles of hindquarters at the dose rate of 7.5 mg kg^−1^ body weight by the i.v. and i.m. route, respectively. Blood samples (4--5 mL) were collected by jugular venipuncture (using contra‐lateral vein from that to which the i.v. dose was administered) in tubes containing 8--10 units heparin per mL of blood at 0, 2.5, 5, 10, 15, 30 min, 1 h, 2, 4, 8, 12, 24, 36, 48, 60 and 72 h following enrofloxacin administration. Subsequently, plasma was separated and analysed. Enrofloxacin and Ciprofloxacin hydrochloride standards were purchased from Sigma Aldrich, St. Louis, Missouri and M.P. Biomedicals, Santa Ana, California USA. All the reagents used for the analysis were of high‐performance liquid chromatography (HPLC) grade. Plasma concentrations of enrofloxacin and ciprofloxacin hydrochloride were determined using HPLC‐Ultraviolet (HPLC‐UV) (Perkin Elmer series 200, Waltham, MA, USA) as per the method previously established in the laboratory (Balaje *et al*. [2013](#vms310-bib-0004){ref-type="ref"}).

The retention time of ciprofloxacin and enrofloxacin was about 6 ± 0.5, 7 ± 0.5 min, respectively, with a peak separation of 1 min. The calibration curves for ciprofloxacin and enrofloxacin are presented in Figs [1](#vms310-fig-0001){ref-type="fig"} and [2](#vms310-fig-0002){ref-type="fig"}, respectively, where *y* is peak area and *x* is the concentration (*μ*g mL^−1^). The linearity (*R* ^2^ = 0.9999) of assay method was evaluated by constructing a calibration curve in the range of 0.01--10 *μ*g mL^−1^. Limit of quantification (LOQ) of enrofloxacin and ciprofloxacin was 0.02 and 0.01 *μ*g mL^−1^. The recoveries validated via repetitive analysis (*n* = 3) of the plasma samples spiked with enrofloxacin and ciprofloxacin were in the range of 90--105%. The precision (interday and intraday) of the assay was less than 5% with an accuracy of more than 95%. The best suited model for pharmacokinetic analysis was determined by visual fit. Various pharmacokinetic parameters were calculated from the log plasma concentration‐time profile of enrofloxacin and ciprofloxacin, using Microsoft Excel for each animal according to standard equations given by Gibaldi & Perrier ([1982](#vms310-bib-0013){ref-type="ref"}). The metabolite conversion ratio (MCR), priming and maintenance dose were estimated by the following formulae:$$\text{Metabolic\ Conversion\ Ratio} = \text{AUC\ of\ ciprofloxacin}/\text{AUC\ of\ enrofloxacin}$$ $$\mspace{6mu}\text{Priming\ dose}{(D)} = C_{p}{(\text{min})}^{\infty} \times V_{d({area})} \times {(e^{\mathit{\beta}\mathit{\tau}})}$$ $$\text{Maintenance\ dose}{(D^{\prime})} = C_{p}{(\text{min})}^{\infty} \times V_{d({area})} \times {(e^{\mathit{\beta}\mathit{\tau}} - 1)}$$

![Standard curve for ciprofloxacin.](VMS3-1-63-g001){#vms310-fig-0001}

![Standard curve for enrofloxacin.](VMS3-1-63-g002){#vms310-fig-0002}

Statistical analysis was performed on various pharmacokinetic and pharmacodynamic parameters using Students *t* test (*P* \> 0.05).

Results and discussion {#vms310-sec-0003}
======================

Pharmacokinetics {#vms310-sec-0004}
----------------

Upon single administration of enrofloxacin (7.5 mg kg^−1^ body weight), concentration -- the time curve was plotted and compartments were decided by visual fit. After i.v. administration of enrofloxacin, both parent drug and ciprofloxacin followed the two‐compartment open model whereas enrofloxacin followed the two‐compartment open model and ciprofloxacin the one‐compartment open model after i.m. administration of enrofloxacin (Figs [3](#vms310-fig-0003){ref-type="fig"},[4](#vms310-fig-0004){ref-type="fig"}). In previous studies, a mono‐compartment open model was used for pharmacokinetic analysis (Balaje *et al*. [2013](#vms310-bib-0004){ref-type="ref"}; Kumar & Jayachandran [2013](#vms310-bib-0019){ref-type="ref"}). The two‐compartment open model followed in the present study was in confirmation with previous study where kinetics in several ruminant species was conducted after administration of ciprofloxacin intramuscularly (Javed *et al*. [2009](#vms310-bib-0016){ref-type="ref"}). Ahangar & Srivastava ([2000](#vms310-bib-0001){ref-type="ref"}) also reported the two‐compartment model for enrofloxacin following i.v. administration at dose rate of 5 mg kg^−1^ body weight. All the pharmacokinetic parameters calculated are presented in Table [1](#vms310-tbl-0001){ref-type="table-wrap"}. Since, enrofloxacin gets metabolized to ciprofloxacin, a pharmacologically active metabolite, it is important to consider the role of the metabolite along with the parent drug for analysing the pharmacokinetics and dynamics of drug preparation.

![Semi logarithmic plot of enrofloxacin after administration at 7.5 mg kg^−1^ body weight through intravenous & intramuscular route.](VMS3-1-63-g003){#vms310-fig-0003}

![Semi logarithmic plot of ciprofloxacin after administration of enrofloxacin at 7.5 mg kg^−1^ body weight through intravenous and intramuscular route.](VMS3-1-63-g004){#vms310-fig-0004}

###### 

Pharmacokinetic parameters of enrofloxacin and ciprofloxacin after administration of enrofloxacin at 7.5 mg kg^−1^ body weight through intravenous and intramuscular route

  Parameter                 Ciprofloxacin i.m.                                          Ciprofloxacin i.v.                                   Enrofloxacin i.m.      Enrofloxacin i.v
  ------------------------- ----------------------------------------------------------- ---------------------------------------------------- ---------------------- ----------------------------------------------------
  *A*\' (*μ*g mL^−1^)       3.59 ± 0.42                                                 9.17 ± 3.53                                          4.29 ± 1.65            --
  *K*a (h^−1^)              0.85 ± 0.12                                                 9.77 ± 2.68[\*](#vms310-note-0002){ref-type="fn"}    3.53 ± 0.99            --
  *t* ~1/2*K*a~ (h)         0.89 ± 0.12                                                 0.09 ± 0.02[\*](#vms310-note-0002){ref-type="fn"}    0.28 ± 0.06            --
  *A* (*μ*g mL^−1^)         --                                                          14.0 ± 0.51                                          4.86 ± 1.30            167.7 ± 4.24[\*](#vms310-note-0002){ref-type="fn"}
  ∞ (h^−1^)                 --                                                          0.37 ± 0.03                                          0.17 ± 0.03            3.10 ± 0.17[\*](#vms310-note-0002){ref-type="fn"}
  *t* ~1/2∞~ (h)            --                                                          1.90 ± 0.17                                          3.62 ± 0.26            0.23 ± 0.01[\*](#vms310-note-0002){ref-type="fn"}
  *B* (*μ*g mL^−1^)         3.50 ± 0.45                                                 1.73 ± 0.14[\*](#vms310-note-0002){ref-type="fn"}    3.04 ± 0.87            1.39 ± 0.08
  *β* (h^−1^)               0.07 ± 0.003                                                0.09 ± 0.007[\*](#vms310-note-0002){ref-type="fn"}   0.09 ± 0.005           0.09 ± 0.003
  *t* ~1/2*β*~ (h)          10.9 ± 0.63                                                 7.95 ± 0.56[\*](#vms310-note-0002){ref-type="fn"}    8.20 ± 0.53            8.12 ± 0.31
  *C* ~max~ (*μ*g mL^−1^)   3.32 ± 0.34                                                 15.1 ± 0.92                                          9.52 ± 0.93            --
  *T* ~max~ (h)             4.00 ± 0                                                    0.25 ± 0                                             1 ± 0                  --
  AUC (*μ*g h mL^−1^)       49.1 ± 4.54                                                 18.6 ± 1.02[\*](#vms310-note-0002){ref-type="fn"}    32.0 ± 9.09            70.5 ± 2.33[\*](#vms310-note-0002){ref-type="fn"}
  AUMC (*μ*g h^2^ mL^−1^)   836.2 ± 91.2                                                223.4 ± 16.9[\*](#vms310-note-0002){ref-type="fn"}   375.4 ± 82.2           207.2 ± 7.58
  *V*d~area~ (L kg^−1^)     --                                                          --                                                   1.46 ± 1.02            1.25 ± 0.08
  *K*el (h^−1^)             0.14 ± 0.007                                                0.59 ± 0.18                                          0.37 ± 0.13            2.41 ± 0.11[\*](#vms310-note-0002){ref-type="fn"}
  MRT (h)                   17.0 ± 0.98                                                 12.1 ± 1.11[\*](#vms310-note-0002){ref-type="fn"}    13.4 ± 1.50            2.95 ± 0.14[\*](#vms310-note-0002){ref-type="fn"}
  *t* ~d~ (h)               --                                                          --                                                   42.9 ± 2.75            42.4 ± 1.62
  *K*12/*K*21               0.69 ± 0.05                                                 4.82 ± 1.84                                          1.64 ± 0.70            6.14 ± 0.68[\*](#vms310-note-0002){ref-type="fn"}
  MCR                       i.m. -- 1.54 ± 0.27[\*](#vms310-note-0002){ref-type="fn"}                                                        i.v. -- 0.27 ± 0.021   

i.v., intravenous; i.m., intramuscular; *A*\', zero time intercept of regression line of absorption phase; *K*a, absorption rate constant; *t* ~1/2~ *K*a, absorption half life; *A*, zero time intercept of regression line of distribution phase; ∞, distribution rate constant; *t* ~1/2∞~, distribution half life; *B*, zero time intercept of regression line of elimination phase; *β*, elimination rate constant; *t* ~1/2*β*~, elimination half life, *C* ~max~, maximum concentration achieved; *T* ~max~, time taken to achieve maximum concentration; AUC, total area under plasma drug concentration time curve calculated by trapezoidal method; AUMC, total area under the first moment of plasma drug concentration time curve; *V*d~area~, volume of distribution; *K*el, elimination rate constant from central compartment; MRT, mean residence time; *t* ~d~, dosing interval; *K*12/*K*21, ratio of rate constants for transfer of drug between central and peripheral compartments; MCR, metabolite conversion ratio. \*Significant difference at *P* \> 0.05 level of significance when compared within enrofloxacin and ciprofloxacin between different routes of administration.
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Drug absorption was rapid after i.m. administration based on the low absorption half‐life (0.28 h) followed by prolonged distribution (*t* ~1/2∞~ = 3.6 h) but the drug elimination followed similar pattern even though drug was administered through different routes. Ciprofloxacin on the other hand showed prolonged residence in the body of buffalo calves after i.m. dosing of enrofloxacin compared to intravenous administration, which might be due to absorption of parent drug from the site of administration and its slower metabolism forming ciprofloxacin in liver resulting in longer elimination half‐life (10.9 h) as well as mean residence time (MRT) (17 h). Both the maximal concentration and time taken to achieve the maximum concentration for ciprofloxacin was higher and earlier after i.v. route than i.m. route.

Since enrofloxacin has an active metabolite (ciprofloxacin), while calculating bioavailability, the total area under plasma drug concentration time curve (AUC) of both parent and metabolite have been taken into consideration. Bioavailability (*F*) of the drug after drug administration through the i.m. route was 91%. This indicated that the parent drug was well absorbed through the i.m. route. Enrofloxacin metabolically converted to ciprofloxacin and also persisted for longer duration in the animal body, resulting in greater AUC of ciprofloxacin after injection of enrofloxacin by the i.m. route than i.v.

Volume of distribution, an indicator of the drug distribution was not significantly altered irrespective of the route of administration as it depends on the type of compound rather than the dose or route of administration.

MRT of enrofloxacin administered intravenously was many fold lesser compared to that after the i.m. route indicating rapid elimination via the first route. On comparing MRT of enrofloxacin to ciprofloxacin following any route of administration, it was found to be higher for later indicating that the parent drug gets metabolized and the metabolite persists in the system for a longer time than the parent compound itself. This further supports the longer persistence of ciprofloxacin following either route.

MCR indicates the conversion of the parent drug (enrofloxacin) to active metabolite (ciprofloxacin). When enrofloxacin was administered intravenously, there was lower conversion of the parent compound to metabolite, indicated by significantly lower MCR, as seen by lower AUC of ciprofloxacin obtained.

PK‐PD integration {#vms310-sec-0005}
-----------------

The maximum plasma concentration achieved after drug administration (*C* ~max~)/minimum inhibitory concentration (MIC) and/or AUC/MIC ratios are the main PK--PD parameters correlating with efficacy of concentration‐dependent antimicrobials (McKellar *et al*. [2004](#vms310-bib-0024){ref-type="ref"}). Using the pharmacodynamic parameters recently established in our laboratory (Balaje *et al*. [2013](#vms310-bib-0004){ref-type="ref"}; Beri *et al*. [2015](#vms310-bib-0005){ref-type="ref"}), PK‐PD indices were calculated to analyse the apparent effectiveness of the drug preparation *in vivo*. The results of PK‐PD integration are presented in Table [2](#vms310-tbl-0002){ref-type="table-wrap"}.

###### 

Integration of PK‐PD data in animals administered with enrofloxacin (7.5 mg kg^−1^ body weight)

  Parameter       Ciprofloxacin i.m.   Ciprofloxacin i.v.                                     Enrofloxacin i.m.   Enrofloxacin i.v.                                      Enrofloxacin i.m.   Enrofloxacin i.v.
  --------------- -------------------- ------------------------------------------------------ ------------------- ------------------------------------------------------ ------------------- -----------------------------------------------------
  *C* ~max~/MIC   369.0 ± 37.7         1680.9 ± 102.7[\*](#vms310-note-0003){ref-type="fn"}   432.5 ± 42.2        --                                                     190.3 ± 18.6        --
  AUC/MIC         5457.0 ± 504.8       2062.0 ± 113.6[\*](#vms310-note-0003){ref-type="fn"}   1453.3 ± 413.2      3204.8 ± 105.7[\*](#vms310-note-0003){ref-type="fn"}   639.5 ± 181.8       1410.1 ± 46.5[\*](#vms310-note-0003){ref-type="fn"}
  *C* ~max~/MBC   207.6 ± 21.2         945.5 ± 57.8[\*](#vms310-note-0003){ref-type="fn"}     264.3 ± 25.8        --                                                     158.6 ± 15.5        --
  AUC/MBC         3069.6 ± 37.7        1159.9 ± 63.9[\*](#vms310-note-0003){ref-type="fn"}    888.1 ± 252.5       1958.5 ± 64.6[\*](#vms310-note-0003){ref-type="fn"}    532.9 ± 151.5       1175.1 ± 38.8[\*](#vms310-note-0003){ref-type="fn"}
  *C* ~max~/MPC   87.4 ± 8.92          398.1 ± 24.3[\*](#vms310-note-0003){ref-type="fn"}     56.6 ± 5.52         --                                                     6.26 ± 0.61         --
  AUC/MPC         1292.5 ± 119.6       488.4 ± 26.9[\*](#vms310-note-0003){ref-type="fn"}     190.3 ± 54.10       419.7 ± 13.8[\*](#vms310-note-0003){ref-type="fn"}     21.0 ± 5.98         46.4 ± 1.53[\*](#vms310-note-0003){ref-type="fn"}

PK‐PD, pharmacokinetic--pharmacodynamic; i.v., intravenous; i.m., intramuscular; *C* ~max~, maximum concentration achieved; MIC, minimum inhibitory concentration; AUC, total area under plasma drug concentration time curve calculated by trapezoidal method; MBC, minimum bactericidal concentration; MPC, mutant prevention concentration. \*Significant difference at *P* \> 0.05 level of significance when compared within enrofloxacin and ciprofloxacin between different routes of administration.
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Balaje *et al*. ([2013](#vms310-bib-0004){ref-type="ref"}) reported MIC, minimum bactericidal concentration (MBC) and mutant prevention concentration (MPC) values of enrofloxacin against *P. multocida* isolates as 0.05, 0.06 and 1.52 *μ*g mL^−1^, respectively. Whereas, Beri *et al*. ([2015](#vms310-bib-0005){ref-type="ref"}) reported MIC, MBC and MPC values of 0.009, 0.016 and 0.038 & 0.022, 0.036 and 0.168 *μ*g mL^−1^ for ciprofloxacin and enrofloxacin, respectively, against *E. coli* and its clinical isolates. Pharmacodynamic parameters of ciprofloxacin against *Pasteurella spp*. is yet to be established in our laboratory.

As the fluoroquinolones are concentration‐dependent drugs with post‐antibiotic effect, PK‐PD indices such as *C* ~max~/MIC or *C* ~max~/MBC or *C* ~max~/MPC and AUC/MIC or AUC/MBC or AUC/MPC are used for interpreting the effectiveness of preparation. These PK‐PD parameters were also calculated for danofloxacin in camels (Aliabadi *et al*. [2003](#vms310-bib-0002){ref-type="ref"}).

It was proposed that *C* ~max~/MIC and/or AUC~24 h~/MIC for ciprofloxacin should be more than 10 and 125, respectively for successful therapy and prevention of emergence of resistance (Forrest *et al*. [1993](#vms310-bib-0011){ref-type="ref"}). Nightingale *et al*. ([2000](#vms310-bib-0025){ref-type="ref"}) suggested that for effective eradication of Gram positive and negative bacteria, an AUC/MIC ratio should be more than 30 and 100, respectively. AUC/MPC ratio of 9--12 was effective in controlling mutations when the inoculum size was between 10^5^ and 10^7^ cfu mL^−1^ (Ferran *et al*. [2007](#vms310-bib-0010){ref-type="ref"}).

The PK/PD indices, such as the *C* ~max~/MPC and AUC~24 h~/MPC were selected in order to predict the *in vivo* applicability of the *in vitro* MPC concept in agreement with other studies (Toutain *et al*. [2002](#vms310-bib-0034){ref-type="ref"}; Olofsson *et al*. [2006](#vms310-bib-0026){ref-type="ref"}). When the bacterial load is very high (in case of acute infection) or in chronic cases there might be chances that some of microorganisms are less sensitive (mutant) to that particular antimicrobial this led to the concept of MPC.

In the present study, values of *C* ~max~/MIC and AUC/MIC for ciprofloxacin were found to be more than that recommended by Forrest *et al*. ([1993](#vms310-bib-0011){ref-type="ref"}). The results from the present study indicate that enrofloxacin and ciprofloxacin can be used effectively for Gram positive and Gram negative bacteria because of their high AUC/MIC ratio (\>\>\>100). With respect to the ability to control mutants, it was found that AUC/MPC ratio was very high in case of *E. coli* (\>\>\>9--12), while moderately higher in the case of *P. multocida* indicating the effectiveness in controlling infection along with eradicating resistance.

Dosage regimen {#vms310-sec-0006}
--------------

Even though fluoroquinolones are concentration dependent, single administration of antibiotic achieving a higher *C* ~max~ is not enough for an effective antibacterial therapy. There is a necessity to maintain the concentration of antibacterial (for AUC) by multiple administrations. Since, *C* ~max~ and AUC are two important pharmacokinetic parameters used in PK‐PD integration, it is necessary to achieve a higher value for maintaining antibacterial activity and against development of resistance irrespective of the post antibiotic effect for fluoroquinolones. So, the calculation of priming and maintenance dose helps in achieving both higher concentration as well as a higher AUC resulting in better antibacterial activity. In the case of mixed infections, we have to take into consideration the range of MICs or when bacterial load is very high (in case of acute infection) or in chronic cases there might be chances that some of microorganisms are less sensitive (mutant) to that particular antimicrobial. In such a situation, multiple administrations become necessary so as to maintain the plasma/serum concentration in the animal body for effective treatment. The priming and maintenance dose were also calculated by Ram *et al*. ([2010](#vms310-bib-0028){ref-type="ref"}) in buffalo calves; Javed *et al*. ([2009](#vms310-bib-0016){ref-type="ref"}) in ruminants; Dumka & Srivastava ([2013](#vms310-bib-0007){ref-type="ref"}) in cross bred calves for various fluoroquinolones.

After calculating the pharmacokinetic and pharmacodynamic parameters, the dosage regimen (*D* and *D*\') was calculated and presented in Table [3](#vms310-tbl-0003){ref-type="table-wrap"}. The calculated priming and maintenance doses of enrofloxacin for the treatment of infectious diseases caused by *E. coli* (MPC ≤ 0.2 *μ*g mL^−1^) with an inter‐dose interval of 24, 36 and 48 h after i.v. administration were found to be 1.95, 5.50, 15.54 and 1.70, 5.25 and 15.29 mg kg^−1^ body weight, respectively. Whereas, the priming and maintenance dose after i.m. administration were 2.39, 6.99, 20.52 and 2.11, 6.71 and 20.23 mg kg^−1^ body weight, respectively. For infections caused by *Pasteurella* spp. (MPC ≤ 1.2 *μ*g mL^−1^), the priming and maintenance dose at an interdose interval of 24, 36 and 48 h were 11.72, 32.98, 93.24 and 10.22, 31.48, 91.74 mg kg^−1^ body weight after intravenous administration.. For the i.m. route priming and maintenance dose at 24, 36 and 48 h interval were 14.36, 41.94, 123.10 and 12.65, 40.24, 121.39 mg kg^−1^, respectively.

###### 

Priming (*D*) and maintenance (D1) doses (mg kg^−1^ B.W.) of enrofloxacin calculated on the basis of the pharmacokinetic data obtained in healthy buffalo calves after intravenous and intramuscular administration at different dosage intervals

                                                               Dosing interval (h)                                                                   
  --------------------------------------------- -------------- --------------------- -------------- -------------- ---------------- ---------------- ---------------
  *Escherichia coli* (MPC -- 0.2 *μ*g mL^−1^)   i.v.           1.95 ± 0.07           1.70 ± 0.08    5.50 ± 0.39    5.25 ± 0.41      15.54 ± 1.75     15.29 ± 1.76
  i.m.                                          2.39 ± 0.35    2.11 ± 0.30           6.99 ± 0.90    6.71 ± 0.85    20.52 ± 2.50     20.23 ± 2.46     
  *Pasteurella sp*. (MPC -- 1.2 *μ*g mL^−1^)    i.v.           11.72 ± 0.43          10.22 ± 0.46   32.98 ± 2.37   31.48 ± 2.43     93.24 ± 10.51    91.74 ± 10.58
  i.m.                                          14.36 ± 2.07   12.65 ± 1.76          41.94 ± 5.37   40.24 ± 5.09   123.10 ± 14.98   121.39 ± 14.77   

MPC, mutant prevention concentration. *D* and D1 is expressed in mg kg^−1^. All the values were expressed in mean ± SEM

John Wiley & Sons, Ltd

In the present day scenario of treating bacterial infections in animals together with an objective to prevent emergence of bacterial resistance, principled antimicrobial usage is important. With this objective in mind, the present study was planned to test the pharmacokinetics of a newer drug preparation in buffalo species which is an important part of future productive livestock but being ignored nutritionally as well as therapeutically making them susceptible to various diseases.

Conclusion {#vms310-sec-0007}
==========

From the present study, it was concluded that the preparation of enrofloxacin used in the present study has a good pharmacokinetic property with longer elimination half‐life as well as MRT when administered intramuscularly. Even though the drug was administered through different routes in buffalo calves, the PK‐PD analysis has shown that the drug and/or its metabolite have persisted for longer periods in the plasma rendering multiple drug administration irrelevant when administered at a dose of 7.5 mg kg^−1^ body weight.
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